Licensing opportunities and technologies are sourced from both the UK’s Medical Research Council and from our drug discovery and diagnostics labs.

MRC Technology is responsible for the technology transfer of patented and protected technologies from the MRC, MRC Technology, and other academic and charitable organisations.

We have technologies available in; Bioinformatics and Diagnostics, Biologics, Cancer, Cardiovascular and Respiratory system, Drug discovery/Drug delivery, Genetics/Genomics/Epigenetics, Infectious diseases/Immunology/Vaccines, Metabolic diseases, Neurobiology, Research tools/Enabling technologies, Software & devices.

If you can’t find what you’re looking for please contact us.

Below is a list of our current therapeutics licensing opportunities.

Alternatively, to view our drug discovery pipeline click here

  • NT4X antibody discovery project for Alzheimer’s disease

    We have developed a unique antibody that specifically recognises toxic Abeta forms as a passive immunotherapy for Alzheimer’s disease.

  • MALT1 Drug discovery project for cancer

    We are developing novel small molecule inhibitors of the protease Malt1, which is a target in lymphoma.

  • PAICS small molecule inhibitors for cancer

    PAICS small molecule inhibitors for cancer.

  • Matrpitase

    Matriptase is serine proteinase and a promising target for the treatment of osteoarthritis. We have generated a number of small molecule inhibitors currently undergoing lead optimisation.

  • Novel use and superior methods of synthesis for the oral iron supplement ferric trimaltol

    Recently the European Commission granted marketing authorisation for ferric trimaltol, as a treatment for adults with iron deficiency anaemia in patients with inflammatory bowel disease.

  • Site-specific incorporation of norbornene, bicyclononyne and cyclopropene as chemical handle for conjugation to tetrazine-based probes

    Powerful general strategy for site-specific labelling of proteins with any probe: allows probes to be placed easily at any position in proteins expressed in prokaryotic and eukaryotic cells and organisms; rapid and quantitative; specific for a user-defined site in a protein; requires no toxic reagents and generates no toxic by-products; demonstrates `turn-on’ fluorescence with minimal off-site or background labelling; allows for labelling with diverse probes.

  • Next generation cell penetrating peptides as a drug delivery system

    Cell penetrating peptides with demonstrated efficacy in transporting biological molecules into cells and improving disease outcome in vivo. Cell penetrating peptides optimised for enhanced tissue delivery with low in vivo toxicity; good serum stability; low immunogenicity; shown to be efficacious in in vivo disease models and industry-scale manufacture has been achieved.

  • ALK

    ALK is a receptor tyrosine kinase that has been implicated in a number of different cancer types. We are developing an antibody-drug-conjugate (ADC) to target ALK in neuroblastoma.

  • ULK1

    The protein kinase ULK1 is a major regulator of autophagy, and blocking this molecule in cancer cells would reduce their capacity to cope with stress. We are screening for small molecule inhibitors of ULK1 as novel cancer therapeutics.

  • Netrin-1

    Netrin-1 is a member of the axonal guidance family of proteins and is an attractive target for therapeutic inhibition of osteolytic diseases. We are developing novel monoclonal antibodies against netrin-1 as therapeutics for osteolytic bone disease.

  • MNK

    MNK is a promising cancer target in a variety of tumour types. We have generated two novel series of small molecule MNK inhibitors that are active against both MNK1 and MNK2.

  • Targeting cancer therapeutics with palladium-activated compounds

    A targeted chemotherapy approach has been developed: the use of non-toxic metallic palladium to modulate the pharmacological activity of small pro-drug molecules in a spatially-controlled manner. The novel chemistry enables targeted delivery of well characterised and effective anti-cancer drugs such as 5-fluorouracil and floxuridine.

  • Ang2 specific biotherapeutic

    An engineered highly specific binder of the pathological ligand angiopoietin-2 (Ang2) has shown that blockade of Ang2, physically or functionally, has significant therapeutic benefit in pre-clinical studies, for example reversing endotoxaemia and promoting tumour regression. Elevated levels of circulating Ang2 occur in pathologiesuch as sepsis, ARDS, retinopathies, pathological angiogenesis and some cancers.

  • HIVcon: a universal, clinically validated HIV-1 vaccine

    A consensus sequence from one of the four major HIV-1 clades A, B, C and D to ensure maximum HIV-1 coverage addresses problem of enormous diversity of HIV-1. This approach delivers the simplicity of design and delivery, requiring only a simple single insert, representative of the major global clades A, B, C, and D equally. Therefore, vaccines based on the conserved regions of the HIV-1 proteome.

  • IL-17BR

    Patients that develop various forms of pulmonary fibrosis are difficult to treat and can have high mortality. We have generated a humanised monoclonal antibody against the IL-25 receptor IL-17BR that shows activity in models of lung fibrosis. The antibody has desirable affinity and biophysical properties and shows efficacy in animal models of lung fibrosis, colitis and asthma.

  • Cardioprotection following heart attack

    A novel small molecule therapeutic for ischemia-reperfusion injury. This novel small molecule therapeutic offers cardioprotection from ischemia-reperfusion injury (IR injury) as exemplified in a mouse model of myocardial infarction. This approach may also be useful for other IR injuries such as following elective surgery, organ transplantation and cerebral infarction.

  • Hormone dependent tumours

    Assay and peptides that could lead to new tumour suppressing therapies for tumours of reproductive tissues such as uterine and prostate cancer. A series of GnRH peptide analogues capable of selectively inhibiting GnRH signalling in tumour cells while not significantly activating unrelated transduction signals. This is combined with an assay to select agents capable of selecting such specific ligands.

  • Wound healing

    GMCSF and PGE synergistic combination for topical application or incorporation into dressings

  • Hormone dependent diseases

    A series of kisspeptin peptide antagonists with low nano-molar affinities for development as therapeutics. Kisspeptin antagonists down-regulate steroid hormones such as testosterone and luteinising but do not completely ablate steroid hormone support so should not result in side effects associated with steroid hormone removal e.g. osteoporosis. The peptides are direct antagonists so no associated initial flare effect normally associated with desensitising agonists.

  • Parkinson’s disease; surgical technique

    Allows unambiguous identification of neural centres for deep brain stimulation treatments

  • GalR2

    We are developing novel small molecule positive allosteric modulators of GalR2 for the treatment of pain.

  • Kir 7.1

    We are looking for small molecule inhibitors of the Kir7.1 potassium channel, which has been implicated in postpartum haemorrhage.

  • TBK1

    Two distinct lead series of small molecule inhibitors with low nM activity. One set of compounds is available for use as research tools; the other series has the potential to be further developed as a therapeutic candidate.

  • IL16

    IL-16 is a cytokine produced by a number of immune and non-immune cells in association with an inflammatory response. We have developed a humanised anti-IL-16 antibody that could have utility in a number of immune-mediated diseases.

Can't find a suitable opportunity?

Please register (below) for alerts on new opportunities or contact us to discuss your requirements.

Don't miss out

Please register now to ensure you receive details of new opportunities as they become available.

Please enter the code into the below box to prove you are human:


You could benefit from our resources and expertise

To discuss any of our current licences and find out about the research areas we are currently exploring please get in touch with our business development team.